Next Article in Journal
A Novel PIFA/KOH Promoted Approach to Synthesize C2-arylacylated Benzothiazoles as Potential Drug Scaffolds
Next Article in Special Issue
Role of Dipeptidyl Peptidase 4 Inhibitors in Antidiabetic Treatment
Previous Article in Journal
Deoxycholic Acid Modulates Cell-Junction Gene Expression and Increases Intestinal Barrier Dysfunction
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Molecules
Volume 27
Issue 3
10.3390/molecules27030727
Review Report
molecules-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
Article
Peer-Review Record

Sitagliptin Is More Effective Than Gliclazide in Preventing  Pro-Fibrotic and Pro-Inflammatory Changes in a Rodent Model of Diet-Induced Non-Alcoholic Fatty Liver Disease

Molecules 2022, 27(3), 727; https://doi.org/10.3390/molecules27030727
by Jing Ren 1, Xiaoyu Wang 1, Christine Yee 1, Mark D. Gorrell 2,3, Susan V. McLennan 1,4,5 and Stephen M. Twigg 1,4,*
Reviewer 1: Anonymous
Reviewer 2: Anonymous
Molecules 2022, 27(3), 727; https://doi.org/10.3390/molecules27030727
Submission received: 24 December 2021 / Revised: 14 January 2022 / Accepted: 18 January 2022 / Published: 22 January 2022
(This article belongs to the Special Issue Diabetes: What Roles Does DPP4 Inhibition Have?)

Round 1

Reviewer 1 Report

Sitagliptin is more effective than Gliclazide in Preventing Pro-Fibrotic 2 and Pro-Inflammatory Changes in a Rodent model of Diet-Induced 3 Non-Alcoholic Fatty Liver Disease

Comments: 

Well designed and well-presented manuscript. I feel amendable deficiencies that are mandatory to be addressed before acceptance.

 

  • Gliclazide is an antidiabetic drug but your findings are contraindicating. In figure 1 b, its noticeable that blood glucose is high in HFD+ Gliclazide group compared to HFD alone group please give reasoning for this contraindication, Similarly the circulating insulin levels and insulin resistance is significantly high in HFD+ Gliclazide group (figure 1 C and D) as appose to your description in the result section that Gliclazide has no effect circulating insulin and insulin resistance. So your figure is opposing your description.

 

  • Histology images are of less resolution and clarity. We could not find much differences in histopathology of HFD and HFD+sitagliptin groups. Due to low resolution the hepatic structures are less demarcated. Please replace or improve the images so that the differences in morphology of different experimental groups should be clearly visible.

 

  • Immunohistochemistry images are also of less resolution and cellular distribution of markers is not well characterized. Include images that will clearly show hepatocytes and visibly indicate the differences in experimental group. If the images will not show clear differences or clear ameliorating effect, then it goes opposite to the claims of the manuscript that Sitagliptin is more effected than HFD and Glicazide in improving fibrotic changes.

 

Regards

 

Author Response

Please see the attachment.

Author Response File: Author Response.docx

Reviewer 2 Report

This article is very interesting. Material and methods and results are correctly represented, discussion is adequate. Histological microphotographs are illustrative, but it is not clear how did you define staining intensity scores and levels 0-4 on histochemical and ICH staining. It should be more precise in Material and Methods.

I have to suggest that authors should put several recent references (within last 5 years).

Author Response

Please see the attachment.

Author Response File: Author Response.docx

Back to TopTop